1 National and global treatment guidelines for COPD include Endobronchial Valves like Zephyr Valves as a recommended treatment option for patients with severe COPD/emphysema, with the Global ...

According to the World Health Organization (WHO), COPD remains ... benefits of the Zephyr Valve therapy," said Steve Williamson, CEO of Pulmonx. "COPD is a debilitating disease.

Building on their successful partnership, the two organizations will launch new resources to educate patients and healthcare providers on innovative treatment options like the Zephyr® ...

More than 11 million people in the United States are living with chronic obstructive pulmonary disease (COPD), including more than 3 million people with emphysema, a type of COPD. This chronic lung ...

She used oxygen 24 hours a day to control her disease and had to stop working ... "I will never see another pulmonologist but him, he can't perform miracles, but he's pretty close." Zephyr Valve, ...

Fintel reports that on December 11, 2024, Citigroup downgraded their outlook for Pulmonx (NasdaqGS:LUNG) from Buy to Neutral.

COPD is a disease that damages your lungs over time. It may start with mild symptoms and then get worse. Treatment can help symptoms and slow disease progression. Chronic obstructive pulmonary ...

The perspectives and priorities of people living with chronic obstructive pulmonary disease should be integrated into the development process of new therapies for COPD, according to a new commentary.

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Pulmonx (LUNG – Research Report), with a price target of ...

is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr ® Endobronchial Valve, Chartis ® Pulmonary Assessment System, LungTraX ...